Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer: results from the prospective multi-center randomized ADEBAR trial - Schwentner, Lukas Paul; Wischnik, Arthur (The breast, 2016)
Gesehen am 13.12.2019